Colonoscopy, endoscopy, fecal calprotectin, CRP, imaging, intestinal ultrasound, and monitoring research.
Page 19 of 33 · 1561 articles
Patients with UC who fail both anti-TNF and JAK inhibitor therapies have limited options. This report suggests tacrolimus can be used as a short-term bridge or in combination to reach another maintenance drug, with many...
The review highlights that colorectal IBD is under-recognized and often mistaken for infectious colitis in sub‑Saharan Africa due to limited diagnostic and specialist resources, which can delay appropriate care.
Itch is a frequent, often severe symptom in PSC that is linked to liver disease severity and worse quality of life. Recognizing and measuring pruritus matters because it significantly affects daily functioning and may...
People with ulcerative colitis face a higher colorectal cancer risk driven in part by chronic inflammation; this review explains the molecular and immune mechanisms behind that risk and highlights biomarkers and...
Compares widely used modelled GBD rates with population-based observations and finds they are not interchangeable for country-year estimates—important for research, surveillance, and policy that rely on these numbers.
Reliable, high-throughput lab methods are a prerequisite for therapeutic drug monitoring (TDM). For people with IBD on JAK inhibitors, validated assays can enable exposure measurement needed for future precision dosing...
In young children, enteric infections can mimic or coexist with VEO‑IBD and change imaging and clinical findings; recognizing both can affect diagnosis and treatment choices.
Population estimates help patients understand how common IBD is and show that ulcerative colitis is more common than Crohn’s in this survey. Knowing prevalence and who is more likely to be diagnosed can help people feel...
This label update restates safety information for ROWASA (a mesalamine rectal formulation) used for distal ulcerative colitis. Patients with IBD should be aware of potential serious hypersensitivity reactions, kidney and...
This label update affects people with IBD because tofacitinib is an approved oral JAK inhibitor for moderately to severely active ulcerative colitis and the label highlights important safety risks (infections, mortality,...
If validated, blood-based AI predictors of organ-specific aging might help flag organs aging faster in people with Crohn’s disease or other conditions, potentially enabling earlier monitoring or research into causes....
Recognizing eye inflammation as a possible early sign of IBD could shorten diagnostic delays and lead to earlier gastroenterology evaluation and treatment, which is especially important for children who often wait years...
This paper evaluates CAR, a simple blood‑based biomarker, in children with IBD and finds it reflects disease severity and changes over time in pediatric Crohn’s disease. That matters because reliable, easy-to-measure...
The study uses generative AI and microbiome/RNA data to search for biomarkers of intestinal fibrosis in Crohn’s disease, which could help spot scarring earlier and potentially prevent worsening complications like...
Market growth and industry activity can affect drug availability, prices, and the pace of new treatments or diagnostics reaching patients. Increased investment in biomarkers and targeted therapies may lead to better...
People with IBD and clinicians often face decisions about whether to stop biologics or small molecules before abdominal surgery.
The study tests whether fewer random biopsies are needed during surveillance colonoscopy with modern high-definition scopes — a question that could change how often biopsies are taken, affect procedure time, costs, and...
Early-phase trials test whether new treatments are safe and show biological activity. This study measures fecal calprotectin, a biomarker of intestinal inflammation, so it could provide early signals about whether ND-12...
People on biologic therapy who lose response often face choices: switch drugs or increase dose. This study shows that escalating doses of infliximab, adalimumab, or vedolizumab frequently led to clinical improvement and...
This project aims to improve prediction of autoimmune disease onset and immunotherapy-related autoimmunity by combining genetics and plasma proteins.
A simple home test for urinary oxalate and Ox/Crea ratio could make monitoring more practical than 24-hour urine collections, helping prevent stone recurrence and allowing earlier treatment adjustments for people at...
This study suggests brain glymphatic function — a fluid-clearance system — may be altered in people with Crohn’s disease and could relate to inflammation and common neuropsychiatric symptoms like fatigue, anxiety,...
Validated, language‑adapted questionnaires let clinicians and researchers measure disease control and quality of life reliably. A Persian IBDcQ-8 helps include Persian‑speaking patients in clinical care and research and...
Many people on ustekinumab who lose response wonder whether increasing dosing frequency helps. This prospective study suggests that empiric intensification to every 4 or 6 weeks raised drug levels and was linked with...
IBD increases risk of osteoporosis; identifying blood proteins that predict later bone loss could help flag higher-risk patients and reveal biological links between gut inflammation and bone health.
The paper reports that hospitalized people with IBD have a higher risk of heparin-induced thrombocytopenia (HIT) and that HIT is associated with worse outcomes (higher mortality, longer stays, higher costs, and more...
The study identifies a cellular mechanism (JAK1-STAT6 pathway) by which upadacitinib can lower IL13RA2 — a molecule tied to inflammation and anti-TNF resistance — which could help explain how JAK inhibitors work in IBD...
Many people with IBD try dietary changes to manage symptoms. This review summarizes what published adult studies report and points toward whole-food and Mediterranean-style patterns as commonly supported approaches.
If confirmed, a gut-derived strain of Lancefieldella parvula that rises with local inflammation could become a mucosal biomarker to help track disease severity or study inflammation mechanisms in IBD.
Hepatitis E can cause elevated liver enzymes in people with IBD on biologics or small molecules. This series found infections were acute and resolved without chronic infection, and advanced therapy could be restarted....
If intestinal ultrasound shows mild isolated hyperemia even with normal bowel wall thickness, this study found a higher chance of treatment changes, steroid use, surgery, or hospitalization within a year — information...
Based on the title and source metadata, this appears to be a clinical study related to Crohn's disease, Inflammatory bowel disease, and Risankizumab. The original article is from Journal of Crohn's & colitis.
Fatigue is common and disabling for people with IBD; this study shows that factors beyond intestinal inflammation—especially central sensitization and psychological symptoms—explain much of fatigue. That means treating...
This study links genetic risk variants to how intestinal epithelial cells respond and regenerate, which is directly relevant to IBD where barrier function and inflammation matter.
Based on the title and source metadata, this appears to be a clinical study related to Ulcerative colitis, Inflammatory bowel disease, and Infliximab. The original article is from Translational gastroenterology and...
1) People with IBD are known to have higher cardiovascular risk; this study directly assessed subclinical carotid atherosclerosis to see if plaque burden explains that risk.
Ustekinumab is already approved for moderate-to-severe Crohn's disease; this real-world study reports encouraging longer-term clinical, biological, and endoscopic outcomes up to 96 weeks and suggests good treatment...
Drug levels and how patients reach remission can differ depending on prior biologic use. For families and clinicians managing pediatric Crohn's, this can affect how infliximab dosing and monitoring are interpreted after...
Better triage methods that combine FIT with demographics and blood biomarkers could reduce unnecessary colonoscopies while keeping sensitivity for colorectal cancer and other serious findings, which matters for...
This work explores a novel, programmable way to deliver anti-inflammatory protein therapy (IL-10) directly in the gut using engineered yeast and wearable electronics. If further developed and translated, it could offer a...
Because intestinal lymphoma can closely mimic Crohn’s disease, recognizing red flags (severe malabsorption, proximal small-bowel involvement, monoclonal gammopathy, poor response to IBD therapy) can change diagnosis and...
Many people with IBD experience persistent fatigue, pain and faecal incontinence even when inflammation is controlled; this programme tested a supported online self-management approach to help those symptoms and assessed...
This registry will track how people with moderate to severe ulcerative colitis do on risankizumab in routine Japanese clinical practice, which may provide information about real-world remission rates and longer-term...
Joint inflammation is a common and impactful extraintestinal issue in IBD; recognizing and treating it appropriately affects symptoms, function, and quality of life.
The study presents an AI method that combines endoscopic images and diagnostic text to predict histological healing in ulcerative colitis, which could help non-invasive assessment and reduce annotation effort in...
A probe that detects both ATP and hypochlorite may offer a more specific optical marker of oxidative/inflammatory activity in IBD models, which could aid research into disease mechanisms and future diagnostic approaches.
Intestinal ultrasound is increasingly used to evaluate Crohn’s disease because it’s noninvasive, repeatable, and can detect activity and some complications—potentially reducing reliance on more invasive tests. Wider...
Patients and clinicians considering sequencing of advanced UC therapies may care because this study reports differences in how long patients stayed on second-line treatment depending on the order of anti-TNF agents and...
